================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): January 2, 2003
----------------------
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
Massachusetts 0-10824 04-2297484
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification Number)
100 Beaver Street
Waltham, Massachusetts 02453
(Address, of principal executive offices, including zip code)
(781) 398-2300
(Registrant's Telephone number including area code)
--------------------
================================================================================
Page 1 of 4 pages.
Item 5. OTHER EVENTS
On January 2, 2003, Genome Therapeutics Corp. issued a press release
announcing that it has established an alliance with Amgen Inc. for the
identification and development of novel therapeutic agents for bone diseases,
including osteoporosis. A copy of this press release is attached to this Current
Report on Form 8-K as Exhibit 99.1.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENOME THERAPEUTICS CORP.
By /s/ Steven Rauscher
---------------------------
Name: Steven Rauscher
Title: Chief Executive Officer
Date: January 2, 2003
EXHIBIT INDEX
99.1 Press Release dated January 2, 2003